1. Introduction {#j_med-2018-0050_s_001}
===============

Invasive fungal infections (IFIs) are serious kinds of fungal diseases that invade the body, grow and reproduce in body tissues, organs and blood, and cause inflammation and tissue damage \[[@j_med-2018-0050_ref_001]\]. Due to the application of high strength, immunosuppressive agents and high-dose chemotherapy for organ transplantation, hematopoietic stem cell transplantation, a variety of catheter in interventional, indwelling intubation ventilator have been widely carried out and the increase of AIDS infection, the incidence of IFI increased significantly \[[@j_med-2018-0050_ref_002]\]. However, the diagnosis of invasive fungal infection was not easy in clinical practice \[[@j_med-2018-0050_ref_003]\]. Generally, invasive fungal infection often requires fungal culture or histopathological examination to confirm the diagnosis. However, fungal culture usually takes 2 to 4 days to obtain results, while histological examination is difficult to achieve in most cases. Therefore, it is important to make a rapid and accurate diagnosis of IFI with a simple and convenient method. 1,3-β-D-glucan is a fungal-cell-wall polysaccharide that can released into the peripheral blood in patients with IFIs. And serum 1,3-β-D-glucan were used as serum biomarker for IFIs diagnosis. However, the diagnostic performance of 1,3-β-D-glucan was quite different according to the previously published studies because of different 1,3-β-D-glucan assays and cutoff value \[[@j_med-2018-0050_ref_004]\]. Therefore, we performed this meta-analysis and pooled the diagnostic efficacy to further assess it clinical value.

2. Methods {#j_med-2018-0050_s_002}
==========

2.1. Publication search strategy {#j_med-2018-0050_s_002_s_001}
--------------------------------

The electronic databases of Medline, Cochrane, Embase, Web of Science, OVID and CNKI were systematic searched to identified the case-control or Cohort studies relevant to diagnostic efficacy of serum 1,3-β-D-glucan for invasive fungal infection. The below terms were used for electronic databases searching. (1) invasive fungal infection/IFI; (2) invasive fungal disease/IFD; (3) 1,3-β-D-glucan/BG/BDG. The language was limited to English and Chinese. In order to identify additional relevant publications, the reference of the included studies were also screened to find potential suitable studies. For studies without enough data to make the meta-analysis, the corresponding authors were contacted by e-mail to obtain further information, if necessary.

2.2. Data and information extraction {#j_med-2018-0050_s_002_s_002}
------------------------------------

Hu Caibao and Zhao Tian independently read the whole paper and extracted the data and information. Any disagreement was consulted to another investigator (Chen Changqin) for consensus. The extracted data and information included (1) The study type (case-control or Cohort); (2) The language of the publication (English or Chinese); (3) The journal name of the paper published; (4) The year of the paper published; (5) The first and the corresponding authors; (6) The diagnosis of invasive fungal infectionreference standard; (7) The cutoff value of serum 1,3-β-D-glucan in each study; (8) The number of true positive, false positive, false negative and true negative; (9) Invasive fungal infection detection methods; (10) The region the study performed. And the above detail information and data were by Zhao Tian and Chen Changqin respectively and cross checked.

2.3. Publication quality evaluation {#j_med-2018-0050_s_002_s_003}
-----------------------------------

The general method quality of the included 37 studies was evaluated through the QUADAS tool byTingyu and Hu Caibao independently with eight questionnaires \[[@j_med-2018-0050_ref_005], [@j_med-2018-0050_ref_006]\]. For each of the question, there was 3 status "yes", "no" and "unclear". "yes" represents high quality, "no" represents low quality and "unclear" represents moderate quality.

3. Statistical analysis {#j_med-2018-0050_s_003}
=======================

The diagnostic efficacy for 1,3-β-D-glucan for invasive fungal infection was pooled by MetaDiSc 1.4 software by the equation of sensitivity=true positive/(true positive+false negative), specificity=true negative/( true negative+ false positive). Subgroup analysis was performed according to different serum 1,3-β-D-glucan cutoff value. The diagnostic parameters were pooled by mixed or random effect model according to the statistical heterogeneity across theincluded studies. The SROC curve was drawn by Stata12.0SE software and the AUC was calculated through sensitivity vs specificity for 1,3-β-D-glucan in diagnosis of invasive fungal infection. P\< 0.05 was considered statistical significant.

4. Results {#j_med-2018-0050_s_004}
==========

4.1. Main characteristic of the individual 37 publications {#j_med-2018-0050_s_004_s_001}
----------------------------------------------------------

As a result of the related electronic databases systematic searching, finally 37 relevant studies were fulfilled the inclusion criteria and included in our present meta-analysis ([Figure 1](#j_med-2018-0050_fig_001){ref-type="fig"}). Among the 37 publications, 15 studies were Cohort designed prospective study and other 22 are case-control publications. The cutoff value for 1,3-β-D-glucan in diagnosis of invasive fungal infection ranged from 7 (pg/mL) to 140 (pg/mL). The general characteristics of the 37 publications were demonstrated in [Table 1](#j_med-2018-0050_tab_001){ref-type="table"}.

![The flowchart of publication searching and studies inclusion](med-13-329-g001){#j_med-2018-0050_fig_001}

###### 

The main characters of the recruited 37 publications

  Study                                              Year   Country          Study type     Method            Cutoff value (pg/mL)   Reference                     tp    fp    fn   tn
  -------------------------------------------------- ------ ---------------- -------------- ----------------- ---------------------- ----------------------------- ----- ----- ---- ------
  Miyazaki \[[@j_med-2018-0050_ref_007]\]            1997   Japan            Case-control   Fungitec G-test   10                     Micobiological culture        17    0     7    36
  Obayashi \[[@j_med-2018-0050_ref_008]\]            1995   Japan            Case-control   Fungitec G-test   20                     Autopsy                       37    0     4    153
  Kawazu \[[@j_med-2018-0050_ref_009]\]              2004   Japan            Cohort         Wako              11                     EORTC/MSG                     6     2     5    123
  Kondori \[[@j_med-2018-0050_ref_010]\]             2004   Sweden           Case-control   Fungitec G-test   20                     Micobiological culture        14    0     0    19
  Odabasi \[[@j_med-2018-0050_ref_011]\]             2004   U.S              Cohort         Fungitell         80                     EORTC/MSG                     18    15    2    248
  Ostrosky-Zeichner \[[@j_med-2018-0050_ref_012]\]   2005   U.S              Case-control   Fungitell         60                     EORTC/MSG                     95    22    22   148
  Pazos \[[@j_med-2018-0050_ref_013]\]               2005   Spain            Cohort         Fungitell         120                    EORTC/MSG                     7     3     1    26
  Pickering \[[@j_med-2018-0050_ref_014]\]           2005   U.S              Case-control   Fungitell         60                     Histopathologic examination   31    10    1    22
  Fujita \[[@j_med-2018-0050_ref_015]\]              2006   Japan            Case-control   Wako              11                     Micobiological culture        72    28    4    147
  Alam \[[@j_med-2018-0050_ref_016]\]                2007   Kuwait           Case-control   Fungitell         80                     EORTC/MSG                     14    0     13   26
  Akamatsu \[[@j_med-2018-0050_ref_017]\]            2007   Japan            Cohort         Fungitec G-test   40                     EORTC/MSG                     12    26    7    130
  Obayashi \[[@j_med-2018-0050_ref_018]\]            2008   Japan            Case-control   Fungitec G-test   30                     Autopsy                       39    9     2    98
  Senn \[[@j_med-2018-0050_ref_019]\]                2008   Switzerland      Cohort         Wako              7                      EORTC/MSG                     20    28    10   85
  Persat \[[@j_med-2018-0050_ref_020]\]              2008   France           Case-control   Fungitell         80                     EORTC/MSG                     70    39    26   123
  Ellis \[[@j_med-2018-0050_ref_021]\]               2008   UAE              Cohort         Fungitell         80                     EORTC/MSG                     36    23    2    19
  Leon \[[@j_med-2018-0050_ref_022]\]                2009   Europe           Cohort         Fungitell         75                     Histopathologic examination   14    105   4    117
  Lunel \[[@j_med-2018-0050_ref_023]\]               2009   Netherlands      Cohort         Fungitell         60                     Micobiological culture        16    12    5    18
  Hachem \[[@j_med-2018-0050_ref_024]\]              2009   U.S              Cohort         Fungitell         80                     EORTC/MSG                     29    2     16   18
  Koo \[[@j_med-2018-0050_ref_025]\]                 2009   U.S              Case-control   Fungitell         80                     EORTC/MSG                     50    124   23   635
  Presterl \[[@j_med-2018-0050_ref_026]\]            2009   Austria          Cohort         Fungitell         40                     Micobiological culture        12    14    11   44
  Racil \[[@j_med-2018-0050_ref_027]\]               2010   Czech Republic   Case-control   Fungitell         80                     EORTC/MSG                     8     55    1    27
  Alexander \[[@j_med-2018-0050_ref_028]\]           2010   U.S              Cohort         Fungitell         60                     EORTC/MSG                     8     54    3    5
  Hirata \[[@j_med-2018-0050_ref_029]\]              2010   Japan            Cohort         Wako              8.9                    EORTC/MSG                     8     2     2    196
  Li J \[[@j_med-2018-0050_ref_030]\]                2010   China            Case-control   Fungitec G-test   20                     Micobiological culture        37    16    1    26
  Zuo XH (1)\[[@j_med-2018-0050_ref_031]\]           2010   China            Case-control   Fungitec G-test   20                     EORTC/MSG                     35    4     5    31
  Zuo XH (2) \[[@j_med-2018-0050_ref_031]\]          2010   China            Case-control   Fungitec G-test   50                     EORTC/MSG                     29    3     11   32
  De Vlieger \[[@j_med-2018-0050_ref_032]\]          2011   Belgium          Cohort         Fungitell         140                    EORTC/MSG                     12    10    2    33
  Posteraro \[[@j_med-2018-0050_ref_033]\]           2011   Italy            Cohort         Fungitell         80                     EORTC/MSG                     15    5     1    74
  Acosta \[[@j_med-2018-0050_ref_034]\]              2011   Spain            Cohort         Fungitell         80                     EORTC/MSG                     7     7     2    31
  Jiang ZM \[[@j_med-2018-0050_ref_035]\]            2011   China            Case-control   Fungitec G-test   20                     Micobiological culture        44    21    2    45
  Yang HQ \[[@j_med-2018-0050_ref_036]\]             2011   China            Case-control   Fungitec G-test   20                     Micobiological culture        423   355   34   1027
  Jin X \[[@j_med-2018-0050_ref_037]\]               2011   China            Case-control   Fungitec G-test   10                     EORTC/MSG                     40    1     5    39
  Metan \[[@j_med-2018-0050_ref_038]\]               2012   Turkery          Case-control   Fungitell         80                     EORTC/MSG                     33    19    17   59
  Liu CH \[[@j_med-2018-0050_ref_039]\]              2012   China            Case-control   Fungitec G-test   20                     EORTC/MSG                     36    6     7    51
  Ding C \[[@j_med-2018-0050_ref_040]\]              2012   China            Case-control   Fungitec G-test   20                     Micobiological culture        42    1     6    29
  Wang QF \[[@j_med-2018-0050_ref_041]\]             2012   China            Case-control   Fungitec G-test   20                     Micobiological culture        47    7     2    75
  Yang D \[[@j_med-2018-0050_ref_042]\]              2013   China            Case-control   Fungitec G-test   20                     Micobiological culture        26    16    9    87
  Zeng WX \[[@j_med-2018-0050_ref_043]\]             2016   China            Case-control   Fungitec G-test   20                     Micobiological culture        38    3     39   478

4.2. Quality assessment of the included studies {#j_med-2018-0050_s_004_s_002}
-----------------------------------------------

Eight items (questions) original from QUADAS (Quality Assessment of Diagnostic Accuracy Studies) were used to assessed the general quality of the included studies. For the QUADAS quality assessment, most of the 37 studies fulfilled the items of "Clear description of study selection criteria "and" acceptable reference standard". However, most of the included studies didn't clearly addressed the item of " withdraw reports". The generally quality of the included 37 publications were showed in [Figure 2](#j_med-2018-0050_fig_002){ref-type="fig"}.

![The general quality of the included 37 studies evaluated by QUADAS](med-13-329-g002){#j_med-2018-0050_fig_002}

4.3. The pooled diagnostic sensitivity {#j_med-2018-0050_s_004_s_003}
--------------------------------------

The I^2^ test of the 37-publication indicated significant heterogeneity (I^2^=83.5%). The diagnostic sensitivity was pooled by random effect model. The combined sensitivity for 1,3-β-D-glucan in diagnosis of invasive fungal infection was 0.83 (95%CI:0.38-0.61), [Figure 3](#j_med-2018-0050_fig_003){ref-type="fig"}.

![Pooled forest plot of sensitivity of 1,3-β-D-glucan in diagnosis of invasive fungal infection.](med-13-329-g003){#j_med-2018-0050_fig_003}

4.4. The pooled diagnostic specificity {#j_med-2018-0050_s_004_s_004}
--------------------------------------

Significant statistical heterogeneity was found in the aspect of pooling the specificity through the I^2^ test (I^2^=95.5%). The pooled diagnostic specificity was 0.81 (95%CI:0.80-0.82) by random effect model, [Figure 4](#j_med-2018-0050_fig_004){ref-type="fig"}.

![Pooled forest plot of specificity of 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g004){#j_med-2018-0050_fig_004}

4.5. The pooled +lr and --lr {#j_med-2018-0050_s_004_s_005}
----------------------------

The statistical heterogeneity for effect size +lr and --lr were evaluated through I^2^ test. And the results indicated statistical significant heterogeneity (P=0.000). Therefore, the data was pooled through random effect. The pooled +lr and --lr were 5.13 (95%CI:3.98-6.62), [Figure 5](#j_med-2018-0050_fig_005){ref-type="fig"} and 0.23 (95%CI:0.18-0.30), [Figure 6](#j_med-2018-0050_fig_006){ref-type="fig"}.

![Pooled forest plot of +lr for 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g005){#j_med-2018-0050_fig_005}

![Pooled forest plot of -lr for 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g006){#j_med-2018-0050_fig_006}

4.6. Pooled diagnostic odds ratio(dor) {#j_med-2018-0050_s_004_s_006}
--------------------------------------

Because of significant statistical heterogeneity across the included 37 studies (I^2^=80.9%), the dor was calculated through random effect model. The combined dor was 29.68 (95%CI:18.94-46.52), [Figure 7](#j_med-2018-0050_fig_007){ref-type="fig"}.

![Pooled forest plot of dor for 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g007){#j_med-2018-0050_fig_007}

4.7. The pooled summary ROC and AUC {#j_med-2018-0050_s_004_s_007}
-----------------------------------

The combined receiver operating characteristic (ROC) curve was calculated by Stata12.0SE software ([Figure 8](#j_med-2018-0050_fig_008){ref-type="fig"}). The area under the ROC curve was 0.91.

![The AUC of the SROC for 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g008){#j_med-2018-0050_fig_008}

4.8. Diagnostic efficacy changes according to cutoff value {#j_med-2018-0050_s_004_s_008}
----------------------------------------------------------

The diagnostic sensitivity, specificity, +lr, -lr and odds ratio changes according to cutoff value were demonstrated in [Figure 9](#j_med-2018-0050_fig_009){ref-type="fig"}. The diagnostic sensitivity, specificity and --lrdid not change a lot for different cutoff value of serum 1,3-β-D-glucan ([Figure 9a](#j_med-2018-0050_fig_009){ref-type="fig"}, [Figure 9b](#j_med-2018-0050_fig_009){ref-type="fig"}, [Figure 9d](#j_med-2018-0050_fig_009){ref-type="fig"}).

![The scatter plot of diagnostic efficacy changes according to cutoff value](med-13-329-g009){#j_med-2018-0050_fig_009}

However, the +lr and dor changed significantly for different cutoff value especially for \<20 (pg/mL) group ([Figure 9c](#j_med-2018-0050_fig_009){ref-type="fig"} and [Figure 9e](#j_med-2018-0050_fig_009){ref-type="fig"}).

4.9. Subgroup analysis {#j_med-2018-0050_s_004_s_009}
----------------------

In order to minimize the clinical heterogeneity, we performed subgroup analysis according to invasive fungal infection detection method, study type and gold diagnostic reference. However, the diagnostic efficacy didn't significant changed for different subgroups ([Table 2](#j_med-2018-0050_tab_002){ref-type="table"}).

###### 

The subgroup analysis of 1,3-β-D-glucan for invasive fungal infection

  Subgroup                 No. of study   Sensitivity       Specificity       AUC
  ------------------------ -------------- ----------------- ----------------- ------
  Method                                                                      
  Fungitell                18             0.76(0.72-0.79)   0.76(0.74-0.78)   0.86
  Fungitec G-test          16             0.87(0.84-0.89)   0.83(0.82-0.85)   0.95
  Wako                     3              0.83(0.76-0.89)   0.90(0.88-0.92)   0.93
  Study type                                                                  
   Cohort                  14             0.75(0.70-0.80)   0.79(0.77-0.81)   0.85
   Case-control            23             0.84(0.82-0.86)   0.82(0.81-0.83)   0.93
  Reference                                                                   
   EORTC/MSG               21             0.76(0.73-0.79)   0.83(0.81-0.84)   0.87
  Micobiological culture   12             0.87(0.84-0.89)   0.81(0.80-0.83)   0.94
  Others                   4              0.92(0.86-0.96)   0.76(0.82-0.80)   0.97

4.10. Publication bias evaluation {#j_med-2018-0050_s_004_s_010}
---------------------------------

The publication bias was evaluate by the Deek's funnel plot ([Figure 10](#j_med-2018-0050_fig_010){ref-type="fig"}) and line regression test. The Deek's funnel plot asymmetry test showed there was no publication bias for 1,3-β-D-glucan in diagnosis of invasive fungal infection of the included 37 studies.

![The funnel plot of publication bias for 1,3-β-D-glucan in diagnosis of invasive fungal infection](med-13-329-g010){#j_med-2018-0050_fig_010}

5. Discussion {#j_med-2018-0050_s_005}
=============

Statistical studies demonstrated that invasive fungal infection(IFI) has significantly increased because of the extensive application of high-dose chemotherapy, glucocorticoids, broad-spectrum antibiotics and immunosuppressive agents, as well as the extensive development of solid organ transplantation and hematopoietic stem cell transplantation \[[@j_med-2018-0050_ref_044], [@j_med-2018-0050_ref_045]\]. Generally, appropriate clinical antifungal treatment is often not timely, which leading to deterioration of the patient's condition, thereafter resulting in high mortality. Therefore, rapid and accurate diagnosis of IFI is particularly important for patients with IFI.

1,3-β-D-glucan is a polysaccharide component of fungal cell wall, which is fungi specific and can't find in other microorganisms infection disease such as bacteria, viruses and mycoplasma.1,3-β-D-glucan assay was widely used clinically for IFI diagnosis with good clinical practice value. Previously studies showed 1,3-β-D-glucan was continuously released into the peripheral blood in patients with IFI. Generally, 1,3-β-D-glucan concentration was very low in serum of healthy people, usually less than 10 pg /mL. However, it serum level elevated significant when invasive fungal infection occurred in patients, which was generally greater than 20 pg /mL. Theoretically, 1,3-β-D-glucan detection may be the ideal method for rapid diagnosis of invasive fungal infections in early stage. However, the sensitivity and specificity of these findings are not completely consistent according to the previously published studies. In order to explicated its diagnostic efficacy, we performed this meta-analysis with 37 case-control or cohort studies and pooled the diagnostic efficacy. In our present, meta-analysis, we included 37 relevant studies with the combined sensitivity, specificity, positive likelihood ratio(+lr), negative likelyhood ratio(-lr) and diagnostic odds ratio(dor) of 0.83 (95%CI:0.38-0.61), 0.81 (95%CI:0.80-0.82), 5.13 (95%CI:3.98-6.62), 0.23 (95%CI:0.18-0.30), and 29.68 (95%CI:18.94-46.52). And the pooled AUC was 0.91. The results indicated that serum 1,3-β-D-glucan assay was a promising biomarker for invasive fungal infection diagnosis.

ROC curve is an accurate and comprehensive method for evaluation diagnostic tests. According to the results of Swets \[[@j_med-2018-0050_ref_046]\], if the area under the ROC curve (AUC) less than 0.5, there is no diagnostic value. The diagnostic value of low with limited clinical value when the AUC between 0.5 \~ 0.7. However, the diagnostic accuracy is high when the AUC is more than 0.7. In this present meta-analysis, we found the pooled AUC was 0.91 which indicated that the diagnostic accuracy is high for serum 1,3-β-D-glucan assay in diagnosis of IFIs.

However, there are several limitations in this study. Firstly, there are some clinical heterogeneity which can lead to unstable results. Secondly, statistical heterogeneity was also existed in pooling the data, which may decrease the statistical power. Thirdly, BDG is present in numerous fungi and is therefore non-specific. However, it could probably be a helpful tool for ruling out an IFI.

6. Conclusion {#j_med-2018-0050_s_006}
=============

Serum 1,3-β-D-glucan assay was a promising biomarker for invasive fungal infection diagnosis. However, because of the non-specificity and heterogeneity across the included studies, it should be further evaluated by high quality multicenter prospective diagnostic studies which can provided more strong evidence.
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